Compare Citius Pharmaceuticals Inc (CTXR) vs Lockheed Martin Corporation (LMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Lockheed Martin Corporation — how do they compare? Citius Pharmaceuticals Inc trades at $0.68 (market cap $20.01M), while Lockheed Martin Corporation trades at $598.13 (market cap $137.96B). The key difference: Lockheed Martin Corporation is far larger — about 6894.6× Citius Pharmaceuticals Inc's market cap, and Lockheed Martin Corporation pays a 2.31% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | LMT | |
|---|---|---|
Market Cap | $20.01M | $137.96B |
Sector | Health | Industrials |
52-Week High | $1.82 | $676.70 |
52-Week Low | $0.48 | $431.56 |
Enterprise Value | $16.23M | $154.71B |
Dividend Yield | — | 2.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.
The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.
Lockheed Martin (LMT) trades at $603.16, up 2.59% with strong technical momentum and bullish moving averages. The company reported mixed Q2 2026 earnings with a beat on EPS but faces margin pressure with net income margin declining to 8.16%. Recent news highlights major defense contracts including a $53.9 billion Patriot missile order and successful testing of next-generation interceptors, supporting the record $230 billion backlog.
Outlook remains positive with analyst consensus at Buy (56.76%) and $608 price target, though risks include execution on massive backlog and margin sustainability. The stock offers steady dividends ($3.45 quarterly) and benefits from elevated defense spending, but valuation multiples (P/E 22.04) require continued earnings growth to justify upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →
